We're Hopeful That Skye Bioscience (NASDAQ:SKYE) Will Use Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech ...
Solid Biosciences (NASDAQ:SLDB) Price Target Raised to $16.00
Solid Biosciences (NASDAQ:SLDB – Free Report) had its price objective boosted by Chardan Capital from $15.00 to $16.00 in a report published on Wednesday morning,Benzinga reports. The brokerage ...
What is Wedbush’s Estimate for RCUS FY2029 Earnings?
Research analysts at Wedbush issued their FY2029 EPS estimates for shares of Arcus Biosciences in a note issued to investors ...
Hosted on MSN2d
Solid Biosciences’ stock soars on early success in DMD gene therapy trial
The trial was able to elicit more than double the microdystrophin gene in patients after 90 days of treatment.
Managed Healthcare Executive2d
Solid Biosciences Reports Positive Data from DMD Gene Therapy Trial
Solid Biosciences’ gene therapy uses a shortened version of the dystrophin protein, which is engineered to mimic the key functions of full-length dystrophin and allows it be delivered more effectively ...
TMCnet2d
NAYA Biosciences Announces Nomination of New Board Members
NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women’s health, today ...
MarketBeat on MSN3d
Solid Biosciences Soars 32% on Trial Data: 189% Upside from Here?
Shares of biotech company Solid Biosciences (NASDAQ: SLDB) skyrocketed on Feb. 18 after the firm released key clinical data.
Solid Biosciences (SLDB) Gets a Buy from Barclays
In a report released today, Gena Wang from Barclays maintained a Buy rating on Solid Biosciences (SLDB – Research Report), with a price target ...